Frontlight ResearchEarly access
TerminatedPhase 1/2
Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
Key facts
- Who runs it
- AlloVir
- Where
- Atlanta, Boston, Buffalo, Chapel Hill, Charleston, Cleveland, Duarte, Durham, Gainesville, Houston, Iowa City, Kansas City, Miami, Milwaukee, Nashville, Richmond, Scottsdale, Seattle, and Winston-Salem, United StatesSee the 21 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1/2
- People taking part
- 17 people enrolled
- Started
- 21 Mar 2022
- Ended
- 31 Jan 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ALVR106
- Placebo
- Record updated
- 6 June 2024
- Why it stopped
- Strategic sponsor decision
Who can take part
- Age
- 17 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Undergone hematopoietic cell transplantation (HCT) ≥21 days or solid organ transplantation (SOT) ≥28 days prior to study treatment administration
- Detection of at least 1 target virus of interest (ie, RSV, influenza, hMPV, and/or PIV)
- Diagnosis of Upper or mild Lower Respiratory Tract Infection
Who cannot take part
- Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone equivalent dose >0.5 mg/kg/day)
- Infection by novel coronavirus disease 2019 (COVID-19)
- For HCT patients, evidence of Grade >2 GVHD; and for SOT patients, any history or evidence of GVHD
Where in United States
- Northside HospitalAtlanta, United States
- Dana-Farber Cancer InstituteBoston, United States
- Roswell Park Comprehensive Cancer CenterBuffalo, United States
- University of North Carolina Lineberger Comprehensive Cancer CenterChapel Hill, United States
- Medical University of South CarolinaCharleston, United States
- The Cleveland Clinic FoundationCleveland, United States
- City of HopeDuarte, United States
- Duke University Medical CenterDurham, United States
- University of Florida Division of Hematology & OncologyGainesville, United States
- Baylor College of MedicineHouston, United States
- MD AndersonHouston, United States
- MD Anderson Cancer CenterHouston, United States
- University of IowaIowa City, United States
- University of Kansas Cancer CenterKansas City, United States
- University of Miami - Sylvester Cancer CenterMiami, United States
- Froedtert Hospital and the Medical College of WisconsinMilwaukee, United States
- Vanderbilt University Cancer CenterNashville, United States
- Virginia Commonwealth UniversityRichmond, United States
- Scottsdale Healthcare Hospitals DBA HonorHealthScottsdale, United States
- Fred Hutchinson Cancer Research CenterSeattle, United States
- Wake ForestWinston-Salem, United States
About the trial
What the trial wants to find out
A study to evaluate ALVR106; an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets four community acquired respiratory viruses: respiratory syncytial virus (RSV), influenza, human metapneumovirus (hMPV), and/or parainfluenza virus (PIV) following hematopoietic cell transplant (HCT) and solid organ transplant (SOT).
The 2 groups in the trial
- PlaceboPlacebo, for comparison
Placebo, visually identical to ALVR106
- ALVR106Existing treatment, for comparison
ALVR106, visually identical to placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
- Record updated
- 6 June 2024